The goal of this pilot clinical trial is to determine the effectiveness of Tirzepatide in patients with persistent obesity (BMI > 30) 12 months after bariatric surgery (Roux-en-Y Gastric Bypass). The investigators also aim to determine the frequency of side effects with Tirzepatide in this patient population. Patients who take tirzepatide 12 months after bariatric surgery will be compared to patients who receive a placebo.

Start Date01 Oct 2024

Sponsor / Collaborator

Vanderbilt University Medical Center

NCT06518837 / Not yet recruitingPhase 2IIT

FITWISE: Feasibility Study of Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer

This clinical trial aims to evaluate the effectiveness of tirzepatide in achieving a 5% or more body weight reduction in patients undergoing adjuvant treatment for hormone receptor-positive, HER2-negative (HR+/Her2-) breast cancer. The study will also assess the safety and tolerability of tirzepatide, its feasibility based on discontinuation rates, and completion of treatment. Secondary objectives include evaluating 3-year invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), changes in BMI and body fat distribution, metabolic markers, and circulating tumor DNA (ctDNA).

Start Date30 Sep 2024

Sponsor / Collaborator

Rutgers State University of New Jersey

[+1]

NCT06073184 / Not yet recruitingPhase 2

Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Grade 1 Cancer of the Endometrium (WE-FiERCE)

The incidence of endometrial cancer is increasing at an alarming rate. This trend parallels the rising rate of obesity, the most significant risk factor for endometrial cancer. Young women with obesity and endometrial cancer or atypical hyperplasia who want to maintain their fertility are treated with progestin therapy, such as progestin intra-uterine device (pIUD), which is associated with a mediocre response rate and high recurrence rate, and does not address the underlying cause, obesity. Therefore, the investigators want to assess whether the addition of a weight-loss drug to pIUD will improve their oncologic, reproductive and metabolic outcomes.

Start Date01 Sep 2024

Sponsor / Collaborator

University Health Network

100 Clinical Results associated with Tirzepatide

100 Translational Medicine associated with Tirzepatide

100 Patents (Medical) associated with Tirzepatide

330

Literatures (Medical) associated with Tirzepatide

01 Mar 2024·Peptides

Recent advances in peptide-based therapies for obesity and type 2 diabetes

Article

Author: Flatt, Peter R ; Conlon, J Michael ; Bailey, Clifford J

Options for the treatment of type 2 diabetes mellitus (T2DM) and obesity have recently been expanded by the results of several large clinical trials with incretin-based peptide therapies. Most of these studies have been conducted with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide, which is available as a once weekly subcutaneous injection and once daily tablet, and the once weekly injected dual agonist tirzepatide, which interacts with receptors for GLP-1 and glucose-dependent insulinotropic polypeptide (GIP). In individuals with T2DM these therapies have achieved reductions of glycated haemoglobin (HbA1c) by > 2% and lowered body weight by > 10%. In some studies, these agents tested in non-diabetic, obese individuals at much higher doses have lowered body weight by > 15%. Emerging evidence suggests these agents can also offer cardio-protective and potentially reno-protective effects. Other incretin-based peptide therapies in early clinical development, notably a triple GLP-1/GIP/glucagon receptor agonist (retatrutide) and a combination of semaglutide with the amylin analogue cagrilintide (CagriSema), have shown strong efficacy. Although incretin therapies can incur adverse gastrointestinal effects these are for most patients mild-to-moderate and transient but result in cessation of treatment in some cases. Thus, the efficacy of new incretin-based peptide therapies is enhancing the opportunity to control body weight and blood glucose and improve the treatment of T2DM and obesity.

22 Jan 2024·Expert opinion on pharmacotherapy

Treatment of obesity with medications binding the glucagon-like peptide 1 receptor: what is the current state of play?

Review

Author: Mondoh, Alvin ; Le Roux, Carel

INTRODUCTION:

Obesity, marked by abnormal fat accumulation, poses significant health risks, necessitating effective therapeutic interventions. The focus of this review is to elucidate the importance of glucagon-like peptide 1 (GLP-1) receptor-binding medications in addressing obesity-related health deteriorations.

AREAS COVERED:

Exploring the mechanisms, efficacy, and safety profiles, this review comprehensively assesses medications selectively or non-selectively binding the GLP-1 receptor for obesity treatment. A meticulous analysis of phase 2 and phase 3 data positions retatrutide, CagriSema, survudotide, tirzepatide, semaglutide, and liraglutide in order of effectiveness. While showcasing their efficacy and safety, the review acknowledges the ongoing phase 3 studies, highlighting the need for further exploration of contraindications, dosage, and potential adverse effects to inform personalized treatment decisions.

EXPERT OPINION:

The ongoing anticipation of long-term benefits, particularly sustained weight loss and cardiovascular outcomes, underscores the significance of future treatment algorithms for addressing the disease of obesity.

International journal of obesity (2005)

What is the pipeline for future medications for obesity?

Review

Author: Melson, Eka ; Papamargaritis, Dimitris ; Ashraf, Uzma ; Davies, Melanie J

Abstract:

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality. Our better understanding of the weight regulation mechanisms and the role of gut-brain axis on appetite has led to the development of safe and effective entero-pancreatic hormone-based treatments for obesity such as glucagon-like peptide-1 (GLP-1) receptor agonists (RA). Semaglutide 2.4 mg once weekly, a subcutaneously administered GLP-1 RA approved for obesity treatment in 2021, results in 15–17% mean weight loss (WL) with evidence of cardioprotection. Oral GLP-1 RA are also under development and early data shows similar WL efficacy to semaglutide 2.4 mg. Looking to the next generation of obesity treatments, combinations of GLP-1 with other entero-pancreatic hormones with complementary actions and/or synergistic potential (such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, and amylin) are under investigation to enhance the WL and cardiometabolic benefits of GLP-1 RA. Tirzepatide, a dual GLP-1/GIP receptor agonist has been approved for glycaemic control in type 2 diabetes as well as for obesity management leading in up to 22.5% WL in phase 3 obesity trials. Other combinations of entero-pancreatic hormones including cagrisema (GLP-1/amylin RA) and the triple agonist retatrutide (GLP-1/GIP/glucagon RA) have also progressed to phase 3 trials as obesity treatments and early data suggests that may lead to even greater WL than tirzepatide. Additionally, agents with different mechanisms of action to entero-pancreatic hormones (e.g. bimagrumab) may improve the body composition during WL and are in early phase clinical trials. We are in a new era for obesity pharmacotherapy where combinations of entero-pancreatic hormones approach the WL achieved with bariatric surgery. In this review, we present the efficacy and safety data for the pipeline of obesity pharmacotherapies with a focus on entero-pancreatic hormone-based treatments and we consider the clinical implications and challenges that the new era in obesity management may bring.

700

News (Medical) associated with Tirzepatide

24 Jul 2024

·www.globenewswire.com

Skye Bioscience Hosts Virtual KOL Event, “Metabolic Rewiring with CB1 Inhibition,” and Details Phase 2 Nimacimab Clinical Trial Design Including Obstructive Sleep Apnea Exploratory Endpoints

Skye introduces collaboration with Beacon Biosignals to evaluate potential impact of Nimacimab on sleep quality and sleep apneaSAN DIEGO, July 24, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, is hosting a virtual KOL event titled “Metabolic Rewiring with CB1 Inhibition” today at 9:00 AM ET. During this event the company and members of its clinical advisory board will discuss the scientific rationale for its Nimacimab peripheral CB1 inhibitor and the CBeyond™ Phase 2 clinical trial design, as well as a collaboration with Beacon Biosignals to evaluate sleep quality and sleep apnea in the Phase 2 trial. Advanced registration is required to participate in the webcast and can be completed by clicking here. The presentation and a replay of the call will also be available on the Company’s website. The event will feature distinguished obesity key opinion leaders combined with Skye’s management team. The KOL event will cover the following topics: Current treatment landscape for obesityMechanism and potential role of peripheral CB1 inhibition as a differentiated and complementary anti-obesity therapeutic pathway to other mechanisms of actionPreclinical and Phase 1 clinical data on NimacimabFinalized CBeyond™ Phase 2 clinical trial goals and designIntroduction of collaboration to assess sleep disturbances in Phase 2 Nimacimab studyOverview of Nimacimab clinical development planQ&A session. “We believe there is a promising opportunity for our peripheral CB1 inhibitor, Nimacimab, to play a distinct and complementary role compared to currently available treatments for weight loss, including GLP-1 receptor agonists,” said Tu Diep, Chief Development Officer of Skye. “The KOLs bring extensive experience and a unique perspective in the rapidly evolving field of obesity, and we are pleased that their knowledge and expertise will be shared with a broad audience in today’s event.” CBeyond™ Phase 2 Clinical Trial Design Skye has amended its open Investigational New Drug (IND) application for Nimacimab with an updated clinical trial protocol for its Phase 2 study. The study is expected to begin screening in August 2024 and provide interim and topline data in Q2 and Q4 2025, respectively. This protocol consists of the following elements: 120 patients across four treatment groups will be enrolled. 80 patients will receive either Nimacimab 200 mg or Nimacimab-matching placebo subcutaneously once-weekly in a double-blinded design.40 patients will receive either Nimacimab + Wegovy® or Nimacimab-matching placebo + Wegovy® once-weekly in a partially-blinded design. Wegovy® will be administered once-weekly following appropriate titration up to a maximum weekly dose of 2.4mg.Patients will be treated for 26 weeks and followed for safety for an additional 13 weeks.Primary endpoint: evaluation of weight loss in the Nimacimab arm vs placebo.Secondary endpoints: safety and tolerability; neuropsychiatric and cognitive evaluation; change in body composition by Dual-Energy X-ray Absorptiometry (DEXA); change in key metabolic parameters; triglycerides; insulin sensitivity; leptin sensitivity.Exploratory endpoints: evaluation of combination of Nimacimab and Wegovy®; evaluation of difference in weight loss between Nimacimab and Wegovy®; evaluation of difference in body composition between Nimacimab and Wegovy®; improvement in sleep.The study will evaluate patients with obesity (≥ 30 kg/m2 to ≤ 45 kg/m2) OR overweight (≥ 27 kg/m2 and < 30 kg/m2) with clinically confirmed diagnosis of at least one of the following weight-related co-morbidities: dyslipidemia, cardiovascular disease, obstructive sleep apnea (OSA) syndrome, or controlled arterial hypertension, among other inclusion criteria.Patients with diabetes will be excluded.This study is being conducted at 18 clinical trial sites in the U.S. Obstructive Sleep Apnea and Beacon Biosignals Collaboration Obesity is a major risk factor for OSA and its detrimental sleep disturbances and related effects. Weight loss via therapeutic drugs can reduce these effects1, and OSA has emerged as an approvable indication comorbid with obesity and has been included in weight-loss drug labelling. Skye will also assess improvement in sleep as an exploratory endpoint in this Phase 2 study of Nimacimab. To facilitate this assessment, Skye has entered into a collaboration with Beacon Biosignals, which has an EEG analytics platform aimed at accelerating the development of therapies in neurology, psychiatry, and sleep medicine. In this trial, Beacon’s FDA 510(k)-cleared Dreem Headband will be used in a subset of 40 patients encompassing all arms of the study to collect sleep data and assess validated sleep endpoints. Multi-night data will be collected following screening, and in weeks 13, 26, and the follow-up period. By integrating Beacon’s advanced sleep monitoring technology platform, the trial will assess improvements in sleep patterns and apnea events, such as sleep efficiency and the apnea-hypopnea index (AHI). 1 Atul Malhotra et al, Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity, New England Journal of Medicine, June 21, 2024 About Nimacimab Nimacimab is a first-in-class humanized monoclonal antibody that acts as a negative allosteric modulator to inhibit CB1 signaling in the periphery. Inhibition of CB1 has shown anti-fibrotic, anti-inflammatory, and metabolic mechanisms of action with potential to address a broad range of diseases with unmet medical needs such as obesity, chronic kidney disease, and metabolic dysfunction-associated steatohepatitis (MASH). About Skye Bioscience Skye is focused on unlocking new therapeutic pathways for metabolic health. Backed by specialist life science investors, Skye’s strategy leverages biologic targets with substantial human proof of mechanism for the development of first-in-class therapeutics with clinical and commercial differentiation. Skye plans to start a Phase 2 clinical trial in obesity in Q3 2024 for Nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, comparing monotherapy and combination arms of Nimacimab and a GLP-1R agonist. For more information, please visit: https://www.skyebioscience.com. CONTACTS Investor Relationsir@skyebioscience.com(858) 410-0266 LifeSci Advisors, Mike Moyermmoyer@lifesciadvisors.com(617) 308-4306 Media InquiriesLifeSci Communications, Michael Fitzhughmfitzhugh@lifescicomms.com(628) 234-3889 FORWARD LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our product development, business strategy, the timing of clinical trials and the therapeutic potential of our therapeutic candidates. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Company’s periodic filings with the Securities and Exchange Commission, including in the “Risk Factors” section of Skye’s most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

Phase 2

23 Jul 2024

·www.drugs.com

Study Finds Big Shift in Who's Using GLP-1 Meds Like Ozempic

TUESDAY, July 23, 2024 -- The boom in using GLP-1 drugs like Ozempic to treat obesity has resulted in a bust regarding the drugs’ original purpose, which was to treat type 2 diabetes, a new study finds. New prescriptions for these drugs have doubled among people who have obesity but not diabetes, investigators found. As a result, drug shortages have triggered a drop in new prescriptions for type 2 diabetes, even though Ozempic and Mounjaro were initially developed as diabetes drugs, the researchers said. Both drugs were later approved for weight loss under different brand names, Wegovy and Zepbound . “Essentially, after the medication was approved for obesity... use took off so quickly that we lost control and vision of how fast people were picking up these medications,” said lead researcher Dr. Ali Rezaie , medical director of the Cedars-Sinai GI Motility Program. For the study, researchers analyzed the medical data of about 45 million Americans between 2011 and 2023. About 1 million people became new GLP-1 users during that period in time, results show. Researchers classified them based on whether they had diabetes, obesity or some other related medical condition. GLP-1 drugs work by adjusting a person’s hormone levels and suppressing appetite. Semaglutide -- the drug sold as Ozempic and Wegovy -- is being prescribed disproportionately to females, whites, and those with a BMI of 30 or more, indicating obesity, results show. The findings were published July 22 in the Annals of Internal Medicine . There has been a notable uptick in GLP-1 use since 2020, Rezaie noted. The U.S. Food and Drug Administration approved semaglutide for use as a weight-loss drug in 2021. “This data suggests that more healthcare providers are seeing the benefits of these medications for treating obesity, which is a significant public health shift,” said lead researcher Dr. Yee Hui Yeo , a clinical fellow in the Karsh Division of Gastroenterology and Hepatology at Cedars-Sinai Medical Center in Los AnGeles. “However, it also raises concerns about potential medication shortages and the need to ensure that patients with diabetes still have access to these treatments,” Yeo said in a Cedars-Sinai news release. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Drug Approval

22 Jul 2024

·www.fiercebiotech.com

Innovent bags another phase 3 win in China for next-gen Lilly GLP-1 drug

Lilly is developing the dual agonist in other parts of the world. Innovent has pulled off another late-phase win for its Eli Lilly-partnered GLP-1 drug candidate, linking the dual agonist to improved outcomes in type 2 diabetes to tee up a filing for approval in China. Lilly granted Innovent rights to the dual GLP-1/glucagon receptor agonist mazdutide in China in 2019. At Lilly, the molecule, which is also called LY3305677, has played second fiddle to tirzepatide—the GLP-1 receptor agonist sold as Mounjaro and Zepbound. As tirzepatide emerged as the star of Lilly’s portfolio, the Big Pharma weighed up whether mazdutide represented a meaningful improvement. Innovent plowed ahead as Lilly mulled its options, reporting phase 3 data in adults with overweight or obesity in January and having a Chinese application for approval in weight management accepted weeks later. The latest update puts Innovent on course to seek approval in China in type 2 diabetes. The study randomized 320 Chinese adults with type 2 diabetes and insufficient glycemic control using diet and exercise alone to take one of two doses of mazdutide or placebo once a week. After 24 weeks, HbA1c, a measure of blood sugar, had fallen by 1.57% and 2.15%, respectively, in the low and high dose mazdutide cohorts. HbA1c fell by 0.14% in the placebo arm. The HbA1c data caused the study to hit its primary endpoint. Innovent said the reduction in HbA1c while on mazdutide was sustained through week 48. The Chinese drugmaker also reported significant weight loss, with patients shedding 9.6% after 48 weeks on the high dose, and improvements in measures such as waist circumference and blood pressure. While cross-trial comparisons can be misleading, the study suggests mazdutide is competitive without providing conclusive evidence that it is an improvement over Lilly’s tirzepatide in type 2 diabetes. Lilly reported a 2.07% reduction in HbA1c after 40 weeks of treatment with the high dose of tirzepatide. HbA1c was higher at baseline in the mazdutide trial, 8.24%, than the tirzepatide study, 7.9%. The two molecules could compete for market share in China. Lilly won Chinese approval for tirzepatide in diabetes in May and added authorization in weight management late last week. Novo Nordisk previously won approval for semaglutide, the GLP-1 medicine it sells as Ozempic and Wegovy, in both indications in China. While potentially competing with mazdutide in China, Lilly is developing the dual agonist in other parts of the world. The Big Pharma began a phase 2 study in adults with overweight or obesity in the U.S. in November. But diabetes isn’t currently an area of active study, with Lilly wrapping up a phase 1 trial in the indication in 2021.

Phase 2Phase 3Drug ApprovalClinical ResultPhase 1

100 Deals associated with Tirzepatide

External Link

KEGG	Wiki	ATC	Drug Bank
D11360	-	-	DB15171

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Obesity	US	Eli Lilly & Co.	08 Nov 2023
Overweight	US	Eli Lilly & Co.	08 Nov 2023
Diabetes Mellitus, Type 2	US	Eli Lilly & Co.	13 May 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Sleep Apnea, Obstructive	NDA/BLA	US	Eli Lilly & Co.	21 Jun 2024
Weight Gain	Phase 3	US	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	AR	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	AU	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	CA	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	FR	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	DE	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	IL	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	MX	Eli Lilly & Co.	03 Jun 2024
Weight Gain	Phase 3	PR	Eli Lilly & Co.	03 Jun 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04844918 (SURMOUNT-J, CTgov)	Phase 3	Obesity	267	Tirzepatide (15 mg Tirzepatide)	akawnqsfup(nsrwrcrjrk) = wimvnficon ifzreobcij (jvqrsprqqf, fkpajcayat - oupserofxr) View more	-	16 Jul 2024
				Placebo (Placebo)	akawnqsfup(nsrwrcrjrk) = vkibrxkqix ifzreobcij (jvqrsprqqf, buyapudsfe - zoeotfgzie) View more
NCT04657003 (SURMOUNT-2, ADA2024) Manual	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	-	Tirzepatide	vocdvcvqnj(mdyrzxfatx) = gvbyhlvtac rhkaephush (ifelhqledq )	Positive	21 Jun 2024
				Placebo	-
NCT05412004 (SURMOUNT-OSA, Pubmed)	Phase 3	Sleep Apnea, Obstructive	-	Tirzepatide 10 mg	rzarhqxlau(vltmzctfyt) = prrvsnqjxm khxigldwmy (qxdnzohexn, -29.3 to -21.2)	Positive	21 Jun 2024
				Tirzepatide 15 mg	rzarhqxlau(vltmzctfyt) = vcbtiujncf khxigldwmy (qxdnzohexn, -33.2 to -25.4)
NCT04166773 (SYNERGY-NASH, Pubmed)	Phase 2	Nonalcoholic Steatohepatitis	190	Tirzepatide 5 mg	tozihexwpe(cibnaqcvbm) = srbicetotq fendpbhwxy (keosthdojm, 17 - 50)	Positive	08 Jun 2024
				Tirzepatide 10 mg	tozihexwpe(cibnaqcvbm) = hczbcmsbux fendpbhwxy (keosthdojm, 29 - 62)
NCT04166773 (SYNERGY-NASH, Biospace \| EASL2024) Manual	Phase 2	Nonalcoholic Steatohepatitis	157	Tirzepatide 5mg	lhjpafbzji(gmlswowuvs) = bbaxyxrgmt wrcqlhvzfy (wkmjglzaon ) View more	Positive	05 Jun 2024
				Tirzepatide 10mg	lhjpafbzji(gmlswowuvs) = isbyniimbz wrcqlhvzfy (wkmjglzaon ) View more
NCT05024032 (SURMOUNT-CN, Pubmed)	Phase 3	Obesity BMI	210	Tirzepatide 10 mg	eupyflihik(uqegixemqk) = ujqdeumjqv pwdydzfbwp (cfckmiiotw, -15.8% - -11.4%)	Positive	31 May 2024
				Tirzepatide 15 mg	eupyflihik(uqegixemqk) = tnxyheywsv pwdydzfbwp (cfckmiiotw, -19.7% - -15.3%)
NCT04660643 (SURMOUNT-4, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	783	Placebo (Placebo)	blkuxjsbuq(arlaweakxl) = yhruqcddmm kvvfwttlqp (ramvsupevg, tcdlseftbz - eyshicefgh) View more	-	22 May 2024
				Tirzepatide (Tirzepatide MTD)	blkuxjsbuq(arlaweakxl) = zajoobxnqd kvvfwttlqp (ramvsupevg, eueptjbxtg - mipigvwzmp) View more
NCT04311411 (CTgov)	Phase 1	Obesity	114	Placebo (Placebo)	ocfmkdavtt(ajwledgphy) = npcqvbuuhx txigrpjhkr (dbfewzvhno, wzftvgvyib - vbquyspgny) View more	-	22 May 2024
				Tirzepatide (Tirzepatide)	ocfmkdavtt(ajwledgphy) = ibvwuzpsgy txigrpjhkr (dbfewzvhno, ijbcrwfkmr - hckeunvbkc) View more
NCT04050553 (CTgov)	Phase 1	Diabetes Mellitus, Type 2 \| Hypoglycemia	42	Placebo	wqhhghaaqg(lsmjvqupju) = wxbqvhbiok xwjstkdhpd (ntlzaonaji, vodzjaofcv - lznsfgfjtv) View more	-	20 May 2024
NCT04657016 (SURMOUNT-3, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	579	Placebo (Placebo)	yzpdrtbfrb(rslrgjcdls) = sqncoqqufs raqqfgarkq (oshsazmnle, nhbdfialzd - vqvnxdvswn) View more	-	16 May 2024
				Tirzepatide (Tirzepatide)	yzpdrtbfrb(rslrgjcdls) = jutddzgqtk raqqfgarkq (oshsazmnle, hfitizjzgv - uklegrvfvc) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis